Results 81 to 90 of about 2,026 (172)
CellsMultiple Sclerosis (MS) therapies effectively modulate peripheral immune responses but largely fail to promote neural repair within the central nervous system.
Ivan Anchesi +8 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 345-356, August 2026.Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le +8 more
wiley +1 more source
Current OncologyThis systematic review and meta-analysis evaluates (1) the effectiveness of psychedelic-assisted therapy (PAT) using psilocybin and ketamine for psychosocial symptoms in adults with cancer, (2) contextualizes findings with non-randomized and exploratory ...
Haley D. M. Schuman +6 more
doaj +1 more source
International Journal of NeuropsychopharmacologyAbstract Background Korea has strict controls on narcotics. Nonetheless, as the impact of research on the therapeutic use of marijuana, psychedelics, etc. discussions on their medical use are beginning in Korea. Aims & Objects The
Sohn, *Inki, Jeong, Jong-Hyun
openaire +1 more source
British Journal of Pharmacology, Volume 183, Issue 16, Page 4715-4734, August 2026.Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli +8 more
wiley +1 more source
Treatment-Resistant Bipolar Depression: Therapeutic Trends, Challenges and Future Directions
Neuropsychiatric Disease and Treatment, 2022 Omar H Elsayed,1 Mete Ercis,2 Mehak Pahwa,1 Balwinder Singh2 1Department of Psychiatry and Behavioral Sciences, University of Louisville, Louisville, KY, USA; 2Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USACorrespondence ...
Elsayed OH, Ercis M, Pahwa M, Singh B
doaj
Psychedelics as novel therapeutic agents for chronic pain: mechanisms and future perspectives
Exploration of NeuroscienceChronic neuropathic pain is a significant public health issue affecting an estimated 1.5 billion individuals worldwide. The mechanisms underlying chronic pain are multifaceted and not fully understood. Chronic pain amplifies specific neural pathways through peripheral and central sensitization triggered by repeated exposure to noxious stimuli ...
Bushra Yasin +3 more
openaire +2 more sources
Editorial: Assessing the consequences of antidepressant treatments
Frontiers in Psychiatry, 2023 Markus Kosel +2 more
doaj +1 more source
Development of the Japanese version of the Ego‐Dissolution Inventory (EDI)
Neuropsychopharmacology ReportsAim Psychedelics have recently gained attention as potential therapeutic agents for various psychiatric disorders. Previous research has highlighted that a diminished sense of self, commonly termed “ego‐dissolution” is a pivotal feature of the ...
Keisuke Kusudo +6 more
doaj +1 more source
Special Issue on the Promise of Psychedelic Pharmacology in Neuropsychiatric Drug Development
Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
Andreas Halman, Ross Corriden
wiley +1 more source